Blogs
Portfolio access agreements – Lessons learnt from Vertex Pharma’s Orkambi
By Jack Rawson, Analyst Email: [email protected] Road to commercialization of Vertex’s CF portfolio The European Commission recently approved Vertex’s combination regimen Symkevi (tezacaftor / ivacaftor;
November 21, 2018
